MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

ONC.US

254.35

-0.88%↓

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

ONC.US

254.35

-0.88%↓

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

ONC.US

254.35

-0.88%↓

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

ONC.US

254.35

-0.88%↓

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

ONC.US

254.35

-0.88%↓

Search

Sanofi SA

Geschlossen

BrancheGesundheitswesen

88.23 0.88

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

87.47

Max

88.42

Schlüsselkennzahlen

By Trading Economics

Einkommen

1.4B

1.9B

Verkäufe

3B

11B

KGV

Branchendurchschnitt

17.216

51.198

EPS

1.79

Dividendenrendite

4.48

Gewinnspanne

17.65

Angestellte

82,878

EBITDA

2.2B

2.8B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+31.16% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

4.48%

2.40%

Nächstes Ergebnis

31. Juli 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-19B

111B

Vorheriger Eröffnungskurs

87.35

Vorheriger Schlusskurs

88.23

Nachrichtenstimmung

By Acuity

39%

61%

136 / 380 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Sanofi SA Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Juni 2025, 16:05 UTC

Wichtige Markttreiber

Nurix Therapeutics Stock Climbs as Sanofi Extends License for STAT6

2. Juni 2025, 09:17 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline -- Update

2. Juni 2025, 05:31 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion

22. Mai 2025, 12:02 UTC

Wichtige Markttreiber
Akquisitionen, Fusionen, Übernahmen

Vigil Neuroscience Shares Surge After Sanofi's Planned Acquisition

22. Mai 2025, 00:06 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi to Buy Vigil Neuroscience for About $470 Million

2. Juni 2025, 13:50 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Blueprint Medicines Soars 26% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2. Juni 2025, 12:33 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Sanofi Portfolio Approach Awaits Proof of Improvement -- Market Talk

2. Juni 2025, 10:50 UTC

Akquisitionen, Fusionen, Übernahmen

Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2. Juni 2025, 10:05 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Sanofi's Blueprint Deal Seems Like Good Fit -- Market Talk

2. Juni 2025, 05:06 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi: Total Equity Value, Including Potential CVR Payments, Represents About $9.5B on Fully Diluted Basis

2. Juni 2025, 05:06 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi: Blueprint Shareholders Also Will Receive One Non-Tradeable Contingent Value Right

2. Juni 2025, 05:05 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi: Deal Represents an Equity Value of Approximately $9.1B

2. Juni 2025, 05:05 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi Will Pay $129.00 Per Share in Cash at Closing

2. Juni 2025, 05:04 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi: Blueprint Is Expected to Enhance Sanofi's Growing Immunology Pipeline

2. Juni 2025, 05:04 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi: Acquisition Includes Rare Immunology Disease Medicine, Ayvakit/Ayvakyt

2. Juni 2025, 05:03 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi to Buy Blueprint Medicines Corporation

2. Juni 2025, 05:02 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi to Acquire Blueprint Medicines Corporation

30. Mai 2025, 08:58 UTC

Heiße Aktien

Stocks to Watch Friday: Dell, Marvell, Gap, Ulta -- WSJ

30. Mai 2025, 08:56 UTC

Market Talk

Sanofi, Regeneron Hit by Trial Disappointment -- Market Talk

27. Mai 2025, 05:03 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi Closes Acquisition of DR-0201 From Dren Bio

27. Mai 2025, 05:00 UTC

Akquisitionen, Fusionen, Übernahmen

Press Release: Sanofi Completes Acquisition Of DR-0201 >SAN.FR

21. Mai 2025, 23:33 UTC

Akquisitionen, Fusionen, Übernahmen

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

21. Mai 2025, 23:32 UTC

Akquisitionen, Fusionen, Übernahmen

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

21. Mai 2025, 23:32 UTC

Akquisitionen, Fusionen, Übernahmen

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

21. Mai 2025, 23:23 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

21. Mai 2025, 23:22 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

21. Mai 2025, 23:20 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

21. Mai 2025, 23:18 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

19. Mai 2025, 11:01 UTC

Market Talk

Diversified Exposure to European Banks Is Required -- Market Talk

15. Mai 2025, 11:04 UTC

Market Talk
Ergebnisse

Spanish, Italian Banks Have Less Upside After Strong Run -- Market Talk

Peer-Vergleich

Kursveränderung

Sanofi SA Prognose

Kursziel

By TipRanks

31.16% Vorteil

12-Monats-Prognose

Durchschnitt 114.266 EUR  31.16%

Hoch 127 EUR

Tief 95 EUR

Basierend auf 17 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Sanofi SA – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

17 ratings

12

Buy

5

Halten

0

Sell

Technischer Score

By Trading Central

91.3 / 96.1Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

136 / 380 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.